Editorial: Special issue: Non-alcoholic fatty liver disease: From molecular basis to therapeutic advances.
作者信息
Nasiri-Ansari Narjes, Kassi Eva
机构信息
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527, Athens, Greece.
Endocrine Unit, 1st Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, 11527, Athens, Greece.
出版信息
Metabol Open. 2023 Jan 13;17:100229. doi: 10.1016/j.metop.2023.100229. eCollection 2023 Mar.
Abstract
摘要
相似文献
1
Editorial: Special issue: Non-alcoholic fatty liver disease: From molecular basis to therapeutic advances.社论：特刊：非酒精性脂肪性肝病：从分子基础到治疗进展
Metabol Open. 2023 Jan 13;17:100229. doi: 10.1016/j.metop.2023.100229. eCollection 2023 Mar.
2
Quantitative assessment of self-management in patients with non-alcoholic fatty liver disease: An unmet clinical need.非酒精性脂肪性肝病患者自我管理的定量评估：未满足的临床需求。
World J Gastroenterol. 2024 Jul 7;30(25):3143-3146. doi: 10.3748/wjg.v30.i25.3143.
3
[Research advances in nonalcoholic fatty liver disease and alcoholic liver disease in 2016].2016年非酒精性脂肪性肝病和酒精性肝病的研究进展
Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):181-186. doi: 10.3760/cma.j.issn.1007-3418.2017.03.005.
4
[Effect of liraglutide in treatment of non-alcoholic fatty liver disease: mechanism of action and research advances].利拉鲁肽治疗非酒精性脂肪性肝病的作用：作用机制及研究进展
Zhonghua Gan Zang Bing Za Zhi. 2017 Jun 20;25(6):473-476. doi: 10.3760/cma.j.issn.1007-3418.2017.06.018.
5
[Advances in the pathogenesis of non alcoholic fatty liver disease].[非酒精性脂肪性肝病发病机制的研究进展]
Orv Hetil. 2017 Jun;158(23):882-894. doi: 10.1556/650.2017.30775.
6
[Non-alcoholic fatty liver disease and steatohepatitis].[非酒精性脂肪性肝病和脂肪性肝炎]
Orv Hetil. 2013 Jul 21;154(29):1124-34. doi: 10.1556/OH.2013.29626.
7
[Non alcoholic fatty liver disease: a new risk factor for cardiovascular disease?].[非酒精性脂肪性肝病：心血管疾病的一个新危险因素？]
Tunis Med. 2013 Mar;91(3):171-4.
8
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates.非酒精性脂肪性肝病的药物治疗：新兴靶点与候选药物
Biomedicines. 2022 Jan 26;10(2):274. doi: 10.3390/biomedicines10020274.
9
Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).社论：用代谢相关脂肪性肝病（MAFLD）取代非酒精性脂肪性肝病（NAFLD）术语的国际共识建议。
Med Sci Monit. 2021 Jul 12;27:e933860. doi: 10.12659/MSM.933860.
10
Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.非酒精性脂肪性肝病患者的治疗：当前观点与展望
Dig Liver Dis. 2006 Nov;38(11):789-801. doi: 10.1016/j.dld.2006.04.009. Epub 2006 Jun 5.
引用本文的文献
1
The effects of medicinal and food homologous substances on blood lipid and blood glucose levels and liver function in patients with nonalcoholic fatty liver disease: a systematic review of randomized controlled trials.药食同源物质对非酒精性脂肪肝患者血脂、血糖及肝功能的影响：一项随机对照试验的系统评价。
Lipids Health Dis. 2023 Aug 29;22(1):137. doi: 10.1186/s12944-023-01900-5.
本文引用的文献
1
Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review.内皮细胞功能障碍与非酒精性脂肪性肝病（NAFLD）：简要综述。
Cells. 2022 Aug 12;11(16):2511. doi: 10.3390/cells11162511.
2
Effect of 8 Weeks milk thistle powder (silymarin extract) supplementation on fatty liver disease in patients candidates for bariatric surgery.8周水飞蓟粉（水飞蓟素提取物）补充剂对肥胖症手术候选患者脂肪肝疾病的影响。
Metabol Open. 2022 May 21;14:100190. doi: 10.1016/j.metop.2022.100190. eCollection 2022 Jun.
3
Liver steatosis, cardiac and renal fibrosis, and hypertension in overweight rats: Angiotensin-(3-4)-sensitive hepatocardiorenal syndrome.超重大鼠的肝脂肪变性、心脏和肾脏纤维化以及高血压：血管紧张素-(3-4)敏感型肝心肾综合征。
Metabol Open. 2022 Mar 18;14:100176. doi: 10.1016/j.metop.2022.100176. eCollection 2022 Jun.
4
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.钠-葡萄糖共转运蛋白 2 抑制剂在非酒精性脂肪性肝病中的作用：超越糖尿病和心脏保护的角色。
Int J Mol Sci. 2022 Mar 13;23(6):3107. doi: 10.3390/ijms23063107.
5
Acute intermittent hypoxia drives hepatic lipogenesis in humans and rodents.急性间歇性低氧可促进人类和啮齿动物的肝脏脂肪生成。
Metabol Open. 2022 Mar 14;14:100177. doi: 10.1016/j.metop.2022.100177. eCollection 2022 Jun.
6
Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD].非酒精性脂肪性肝病（NAFLD）患者纤维化的无创评估
Metabol Open. 2022 Jan 5;13:100158. doi: 10.1016/j.metop.2021.100158. eCollection 2022 Mar.
7
Hepatic P38 Activation Modulates Systemic Metabolism Through Fgf21-Mediated Interorgan Communication.肝脏P38激活通过Fgf21介导的器官间通讯调节全身代谢。
Diabetes. 2021 Oct 21. doi: 10.2337/db21-0240.
8
DRAK2-SRSF6-regulated RNA alternative splicing is a promising therapeutic target in NAFLD/NASH.DRAK2-SRSF6调控的RNA可变剪接是NAFLD/NASH中一个有前景的治疗靶点。
Metabol Open. 2021 Dec 8;13:100157. doi: 10.1016/j.metop.2021.100157. eCollection 2022 Mar.
9
Emerging roles for stress kinase p38 and stress hormone fibroblast growth factor 21 in NAFLD development.应激激酶p38和应激激素成纤维细胞生长因子21在非酒精性脂肪性肝病发展中的新作用。
Metabol Open. 2021 Nov 30;12:100153. doi: 10.1016/j.metop.2021.100153. eCollection 2021 Dec.
10
Protective effects of cerium oxide nanoparticles in non-alcoholic fatty liver disease (NAFLD) and carbon tetrachloride-induced liver damage in rats: Study on intestine and liver.氧化铈纳米颗粒对大鼠非酒精性脂肪性肝病（NAFLD）及四氯化碳诱导的肝损伤的保护作用：肠道与肝脏的研究
Metabol Open. 2021 Nov 18;12:100151. doi: 10.1016/j.metop.2021.100151. eCollection 2021 Dec.
Zotero 插件